PHA-543613

An agonist of alpha7 nAChRs, selective for alpha7 nAChRs over alpha4beta2-, alpha4beta4-, alpha3beta2-, or alpha3beta4 subunit-containing nAChRs and 5-HT3 (EC50s = 0.03, >100, >50, >100, >100, and 11 µM, respectively, in calcium mobilization assays), prevents decreases in the number of retinal ganglion cells in a rat model of glaucoma when applied topically, improves sensorimotor deficits and brain edema in a mouse model of intracerebral hemorrhage, increases the time spent with the novel object in the novel object recognition test and reverses amphetamine-induced auditory gating deficits in rats at 1 mg/kg, reduces food intake and body weight in rats. Formulation: A solid. InChI: InChI=1S/C15H17N3O2/c19-15(12-7-11-3-6-20-14(11)8-16-12)17-13-9-18-4-1-10(13)2-5-18/h3,6-8,10,13H,1-2,4-5,9H2,(H,17,19)/t13-/m1/s1. InChIKey: IPKZCLGGYKRDES-CYBMUJFWSA-N. SMILES: O=C(C1=NC=C(OC=C2)C2=C1)N[C@@H]3CN4CCC3CC4